Latest Novartis Stories
COSENTYX(TM) (secukinumab), recently FDA-approved to treat plaque psoriasis, will be available for patients through the nation's largest independent specialty pharmacy. FLINT,
BASEL, Switzerland, March 3, 2015 /PRNewswire/ -- Syngenta announced today the successful issue of a EUR 500 million Eurobond with a maturity of 121/2 years and a coupon
LONDON, March 3, 2015 /PRNewswire/ -- Report Details Vaccines and their technology - your guide to developments, opportunities and revenues See what the future
- Array to receive $85 million upfront payment from Novartis - BOULDER, Colo., March 2, 2015 /PRNewswire/ -- Following announcements from both Novartis and GlaxoSmithKline regarding
Exemplary companies and organizations to be honored March 3 during 2015 ASAP Global Alliance Summit for outstanding partnering, alliance programs, and collaboration efforts ranging from combatting
CRANFIELD, England, February 26, 2015 /PRNewswire/ -- Now in its fifth year, the Productive Innovation Index (PII) celebrates the top 30 pharmaceutical companies most successful
- Farydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD1 EAST HANOVER, N.J., Feb.
As Syngenta Lawsuit Filing Continue Wright & Schulte LLC Is Holding A Series of Public Meetings To Provide Important Legal Information to Ohio Farmers Who May Have Incurred Significant Financial
- In medieval musical notation, a sign or neume denoting a shake or trill.